triamterene Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2728	396-01-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: triamterene diurene pterofen pterophene triamteren triamteril triteren	A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. Molecular weight: 253.27 Formula: C12H11N7 CLOGP: 1.61 LIPINSKI: 0 HAC: 7 HDO: 3 TPSA: 129.62 ALOGS: -2.42 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

triamterene
diurene
pterofen
pterophene
triamteren
triamteril
triteren

A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.

Molecular weight: 253.27
Formula: C12H11N7
CLOGP: 1.61
LIPINSKI: 0
HAC: 7
HDO: 3
TPSA: 129.62
ALOGS: -2.42
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.03 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	13.15 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	51 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	13 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	63 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.42 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4.30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Aug. 10, 1964	FDA	CONCORDIA PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Crystal nephropathy	49.89	11.41	18	26266	843	53321939
Blood potassium decreased	44.37	11.41	75	26209	40385	53282397
Exposure during pregnancy	44.03	11.41	5	26279	124855	53197927
Synovitis	41.58	11.41	3	26281	107890	53214892
Hyponatraemic encephalopathy	37.23	11.41	11	26273	271	53322511
Acquired haemophilia	37.15	11.41	15	26269	957	53321825
Systemic lupus erythematosus	35.50	11.41	9	26275	125405	53197377
Lower respiratory tract infection	33.75	11.41	3	26281	90978	53231804
Off label use	32.13	11.41	122	26162	472090	52850692
Myocardial infarction	31.41	11.41	114	26170	99240	53223542
Rheumatoid arthritis	31.10	11.41	68	26216	314463	53008319
Cerebrovascular accident	29.38	11.41	116	26168	105058	53217724
Hand deformity	28.44	11.41	4	26280	84845	53237937
Oedema peripheral	28.38	11.41	162	26122	170625	53152157
Gastrooesophageal reflux disease	27.97	11.41	97	26187	82566	53240216
Coronary artery disease	27.81	11.41	55	26229	33382	53289400
Cardiac failure congestive	27.28	11.41	104	26180	92653	53230129
Osteoarthritis	26.76	11.41	86	26198	70400	53252382
Dizziness	26.04	11.41	289	25995	371970	52950812
Hyponatraemia	25.80	11.41	114	26170	108493	53214289
Drug intolerance	25.11	11.41	39	26245	205454	53117328
Pyrexia	24.38	11.41	109	26175	403084	52919698
Hypokalaemia	24.22	11.41	103	26181	96414	53226368
Drug ineffective	23.88	11.41	273	26011	816972	52505810
Intentional overdose	22.92	11.41	3	26281	67202	53255580
Focal segmental glomerulosclerosis	22.00	11.41	12	26272	1513	53321269
Glossodynia	21.91	11.41	11	26273	100280	53222502
Infusion related reaction	20.62	11.41	28	26256	155929	53166853
Feeling abnormal	20.31	11.41	125	26159	135176	53187606
Ventricular tachycardia	19.56	11.41	33	26251	17729	53305053
C-reactive protein increased	18.96	11.41	5	26279	67881	53254901
Product use issue	18.51	11.41	25	26259	139559	53183223
Thinking abnormal	18.00	11.41	24	26260	10484	53312298
Neutropenia	17.78	11.41	32	26252	159153	53163629
Blood pressure increased	17.58	11.41	124	26160	140355	53182427
Diabetic neuropathy	17.33	11.41	15	26269	4012	53318770
Myocardial ischaemia	17.08	11.41	26	26258	12818	53309964
Transient ischaemic attack	16.78	11.41	47	26237	35678	53287104
Transient acantholytic dermatosis	16.63	11.41	4	26280	43	53322739
Depression	16.57	11.41	150	26134	182902	53139880
Insomnia	16.28	11.41	152	26132	186920	53135862
Product dose omission issue	15.83	11.41	154	26130	191466	53131316
Product use in unapproved indication	15.00	11.41	20	26264	112269	53210513
Febrile neutropenia	14.73	11.41	18	26266	104918	53217864
Appetite disorder	14.49	11.41	17	26267	6526	53316256
Oedema	14.00	11.41	73	26211	74273	53248509
Anxiety	13.84	11.41	153	26131	196551	53126231
Asthenia	13.51	11.41	241	26043	343349	52979433
General physical health deterioration	13.50	11.41	33	26251	146909	53175873
Myalgia	13.43	11.41	112	26172	133379	53189403
Skin discolouration	13.41	11.41	43	26241	35149	53287633
Therapeutic product effect decreased	13.38	11.41	26	26258	125629	53197153
Deep vein thrombosis	13.33	11.41	78	26206	82835	53239947
Carpal tunnel syndrome	13.32	11.41	28	26256	17739	53305043
Dry skin	13.19	11.41	51	26233	45709	53277073
Intentional product use issue	13.00	11.41	10	26274	72484	53250298
Vitamin B6 deficiency	12.92	11.41	4	26280	116	53322666
Lacunar infarction	12.79	11.41	12	26272	3562	53319220
Hyperlipidaemia	12.64	11.41	29	26255	19486	53303296
Wound	12.54	11.41	16	26268	91541	53231241
Suicide attempt	11.80	11.41	7	26277	58161	53264621
Overdose	11.72	11.41	22	26262	107714	53215068
Back pain	11.70	11.41	171	26113	234076	53088706

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product packaging quantity issue	62.50	14.61	18	8128	813	32504567
Coronary artery disease	36.31	14.61	53	8093	49653	32455727
Myocardial infarction	35.17	14.61	89	8057	125587	32379793
Cerebrovascular accident	27.17	14.61	64	8082	86256	32419124
Dizziness	25.56	14.61	112	8034	209506	32295874
Cardiac failure congestive	20.56	14.61	57	8089	84795	32420585
Lymphopenia	19.55	14.61	21	8125	14435	32490945
Angioedema	18.67	14.61	33	8113	36256	32469124
Completed suicide	17.54	14.61	57	8089	92460	32412920
Activated partial thromboplastin time prolonged	16.49	14.61	15	8131	8440	32496940
Off label use	16.01	14.61	33	8113	306287	32199093
Electrocardiogram U wave present	15.40	14.61	3	8143	23	32505357
Ulcer haemorrhage	15.16	14.61	9	8137	2633	32502747
Bundle branch block left	14.83	14.61	12	8134	5767	32499613

Pharmacologic Action:

Source	Code	Description
ATC	C03DB02	CARDIOVASCULAR SYSTEM DIURETICS ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS Other potassium-sparing agents
FDA PE	N0000008859	Decreased Renal K+ Excretion
FDA PE	N0000175359	Increased Diuresis
FDA EPC	N0000175418	Potassium-sparing Diuretic
MeSH PA	D004232	Diuretics
MeSH PA	D062686	Epithelial Sodium Channel Blockers
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D045283	Natriuretic Agents
MeSH PA	D026941	Sodium Channel Blockers
CHEBI has role	CHEBI:35498	diuretics
CHEBI has role	CHEBI:38633	Na channel blocker

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Edema	indication	267038008
Peripheral Edema due to Chronic Heart Failure	indication
Pulmonary Edema due to Chronic Heart Failure	indication
Hypokalemia	off-label use	43339004
Anuria	contraindication	2472002	DOID:2983
Hypercholesterolemia	contraindication	13644009
Hyperkalemia	contraindication	14140009
Secondary angle-closure glaucoma	contraindication	21571006
Hypovolemia	contraindication	28560003
Dehydration	contraindication	34095006
Hyperuricemia	contraindication	35885006	DOID:1920
Diabetes mellitus type 2	contraindication	44054006	DOID:9352
Diabetes mellitus type 1	contraindication	46635009	DOID:9744
Acidosis	contraindication	51387008
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Sympathectomy	contraindication	57071006
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Hypochloremic alkalosis	contraindication	70134007
Hepatic coma	contraindication	72836002	DOID:12550
Diabetes mellitus	contraindication	73211009	DOID:9351
Megaloblastic anemia due to folate deficiency	contraindication	85649008	DOID:14026
Hyponatremia	contraindication	89627008
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007
Hypomagnesemia	contraindication	190855004
Acute pancreatitis	contraindication	197456007	DOID:2913
Disease of liver	contraindication	235856003	DOID:409
Neonatal hyperbilirubinemia	contraindication	281610001
Pregnancy, function	contraindication	289908002
Azotemia	contraindication	445009001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	6.22	Basic
pKa2	5.5	Basic
pKa3	2.21	Basic
pKa4	0.54	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Amiloride-sensitive sodium channel, ENaC	Ion channel	P37088 P51168 P51170	SCNNA_HUMAN SCNNB_HUMAN SCNNG_HUMAN	BLOCKER	IC50	5.30	IUPHAR	CHEMBL
Solute carrier family 12 member 1	Transporter	Q13621	S12A1_HUMAN				WOMBAT-PK
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	5	DRUG MATRIX
Caspase-1	Enzyme	P29466	CASP1_HUMAN		IC50	5.44	DRUG MATRIX
Cathepsin G	Enzyme	P08311	CATG_HUMAN		IC50	5.13	DRUG MATRIX
Pteridine reductase 1	Enzyme		PTR1_LEIMA		Ki	5.47	CHEMBL

External reference:

ID	Source
4017902	VUID
N0000146253	NUI
D00386	KEGG_DRUG
4017902	VANDF
C0040869	UMLSCUI
CHEBI:9671	CHEBI
DX2	PDB_CHEM_ID
CHEMBL585	ChEMBL_ID
DB00384	DRUGBANK_ID
D014223	MESH_DESCRIPTOR_UI
1266	INN_ID
5546	PUBCHEM_CID
4329	IUPHAR_LIGAND_ID
WS821Z52LQ	UNII
10763	RXNORM
5617	MMSL
80875	MMSL
d00396	MMSL
002315	NDDF
12512008	SNOMEDCT_US
387053007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
MAXZIDE	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0460	TABLET	75 mg	ORAL	NDA	20 sections
MAXZIDE-25	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0464	TABLET	37.50 mg	ORAL	NDA	20 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0378-1352	TABLET	37.50 mg	ORAL	NDA	23 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0378-1355	TABLET	75 mg	ORAL	NDA	23 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0378-2537	CAPSULE	37.50 mg	ORAL	ANDA	21 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0527-1632	CAPSULE	37.50 mg	ORAL	ANDA	20 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0591-0348	TABLET	75 mg	ORAL	ANDA	19 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0591-0424	TABLET	37.50 mg	ORAL	ANDA	19 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0615-1333	CAPSULE	37.50 mg	ORAL	ANDA	23 sections
Triamterene hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0615-3583	TABLET	37.50 mg	ORAL	ANDA	23 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0781-2074	CAPSULE	37.50 mg	ORAL	ANDA	23 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0781-2715	CAPSULE	50 mg	ORAL	ANDA	23 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	10135-581	CAPSULE	37.50 mg	ORAL	ANDA	20 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	10544-049	TABLET	37.50 mg	ORAL	ANDA	19 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	10544-076	TABLET	37.50 mg	ORAL	NDA	22 sections
Triamterene hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	10544-080	TABLET	75 mg	ORAL	ANDA	23 sections
Triamterene hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	10544-536	TABLET	37.50 mg	ORAL	ANDA	23 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	10544-537	TABLET	75 mg	ORAL	ANDA	19 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	16590-338	TABLET	37.50 mg	ORAL	ANDA	19 sections
Triamterene hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	21695-496	TABLET	37.50 mg	ORAL	ANDA	21 sections
Triamterene hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	21695-497	TABLET	75 mg	ORAL	ANDA	21 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	21695-839	CAPSULE	37.50 mg	ORAL	ANDA	23 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	33261-365	TABLET	75 mg	ORAL	ANDA	19 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	33261-952	TABLET	37.50 mg	ORAL	ANDA	19 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	35356-974	CAPSULE	37.50 mg	ORAL	ANDA	24 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	42291-841	CAPSULE	37.50 mg	ORAL	ANDA	20 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	42291-842	TABLET	37.50 mg	ORAL	ANDA	19 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	43063-424	TABLET	37.50 mg	ORAL	NDA	23 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	45865-402	CAPSULE	37.50 mg	ORAL	ANDA	24 sections
Triamterene and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	50090-0372	TABLET	75 mg	ORAL	ANDA	19 sections